Prescription to OTC Switch Process

How a medicine switches from prescription to over-the-counter depends on the jurisdiction, but the logic is the same everywhere. The marketing authorisation holder applies to the regulator. It must show that none of the legal grounds for keeping the product on prescription still apply. And it must show that patients can choose and use the product safely, guided only by its label and leaflet. Where the legal mechanism sits differs: in the EU and UK the switch is a change to the existing marketing authorisation; in the US it is an NDA filing (or a monograph order); in Canada it is a change to the Prescription Drug List.

Approach: I read the EU rules on classification (Directive 2001/83/EC, Title VI) and the Commission's Notice to Applicants switch guideline, the UK Human Medicines Regulations 2012 and US 21 CFR Part 314. I also opened official FDA, MHRA and Health Canada pages. I couldn't open the eCFR text of 21 CFR 310.200 directly, so its approval standard below is as FDA quotes it.

EU (Directive 2001/83/EC)

• Legal test: Every marketing authorisation must state whether the product is "subject to medical prescription" or "not subject to medical prescription" ^[1]. A product needs a prescription if any of four criteria in Article 71(1) applies:

  • it is likely to be dangerous without medical supervision, even when used correctly;
  • it is frequently and very widely used incorrectly;
  • its activity or side effects need further investigation;
  • it is normally given parenterally (by injection).

  Products that meet none of these are non-prescription (Article 72) ^[2][3].

• Ways to bring a product within OTC limits: Under Article 71(4), the authority "may waive" these criteria with regard to the maximum single or daily dose, strength, pharmaceutical form, packaging or other conditions of use ^[2].

• Reclassification: When new facts come to light, authorities "shall examine and, as appropriate, amend the classification" (Article 74) ^[4].

• Procedure:

  • Centrally authorised products: a Type II variation (or an extension application, for example if a new strength is needed), or a separate standalone application. CHMP gives an opinion and a Commission Decision authorises the change.
  • National, mutual recognition and decentralised authorisations: each competent authority decides for itself ^[5].

• Dossier (Commission switch guideline):

  • An expert overview that shows why none of the prescription criteria apply.
  • Safety data covering interactions, misuse and overdose, and the risk of wrong self-diagnosis or delayed diagnosis.
  • Label and leaflet wording, which "will be closely examined".
  • Efficacy data only if the indication or posology changes.
  • Exposure: substances suitable for OTC supply "normally" have five years of widespread prescription use, though a shorter period may be accepted ^[5].

  The guideline also sets out what the authority looks at: self-assessability of the condition, the risk that symptoms of a serious disease are masked, and how good the patient information is ^[6].

• Incentive: If the switch rests on "significant" pre-clinical tests or clinical trials (for example actual-use studies), those results get one year of protection against other applicants (Article 74a) ^[7]. The applicant must claim this in Module 1 ^[5][8].

UK (MHRA)

• Categories: Regulation 62 requires every UK marketing authorisation to state whether the product is prescription-only (POM), pharmacy (P) or general sale (GSL). The POM criteria in Regulation 62(3) mirror the EU's. GSL is allowed only if the product "can with reasonable safety be sold or supplied" without a pharmacist (Regulation 62(5)) ^[9].
• Routes (MHRA guidance, Feb 2025):
  • Simple: based on an analogous product that has already been reclassified. Filed as a Type IB variation, or a Type II if supporting data need assessing.
  • Major: a Type II variation. MHRA "strongly advised" scientific advice beforehand.
• Major timetable:
  • Day 60: assessment ends and a request for further information goes out; the applicant has 60 days to reply.
  • Day 90 to 120: at most two such requests before review by the Commission on Human Medicines (CHM).
  • Innovative switches may first go to a stakeholder group.
  • Approval at about day 160, or about day 225 if a 21-day public consultation is held.
  • If CHM gives no advice, the application is downgraded to "standard" and 50% of the fee is refunded.
• Scope limits: One authorisation cannot hold two legal statuses. New indications and wider posology are outside a reclassification variation, although restricting them is allowed. MHRA publishes a Public Assessment Report within 60 days of approval.

US (FDA)

• Pathways (FDA Rx-to-OTC switches):
  • A full switch is filed as an efficacy supplement to the approved NDA, or as a 505(b)(2) application.
  • A partial switch (some uses go OTC while others stay on prescription) needs a new NDA.
• Data: safety and efficacy data plus postmarketing safety data, and label comprehension and self-selection studies.
• Approval standard: FDA approves when prescription status is "not necessary for the protection of the public health" and the drug is "safe and effective for use in self-medication as directed in proposed labeling" (21 CFR 310.200(b), as quoted by FDA).
• ACNU option: If labeling alone cannot ensure correct self-selection or use, the sponsor can propose an "additional condition for nonprescription use" (ACNU).
  • It requires a separate application, not a supplement.
  • The application must show the condition is necessary and that it works.
  • The OTC version with an ACNU may be sold alongside the prescription version ^[10].
• Monograph route: Since the CARES Act, an OTC monograph can also be amended by administrative order or an OTC Monograph Order Request (FDA OTC overview).

Canada (Health Canada)

• Submission: The company files a submission under the Food and Drug Regulations asking to remove the ingredient (for specified conditions of use) from the Prescription Drug List.
• Review: Assessors judge whether a practitioner is still needed, and the Prescription Drug Status Committee makes a recommendation.
• Consultation and timing: A 75-day public consultation follows. Removal takes effect 6 months after the notice of intent is posted (Health Canada PDL process).
• Guidance: Health Canada's guidance "Switching from prescription to non-prescription status" was revised in August 2024 (overview).

That Health Canada page does not cover provincial scheduling, so I have not covered it here.